FilingFirehose · custom report

TCRT — Alaunos Therapeutics, Inc.

SEC filings analysis · 6 filings reviewed (last 12 months) · generated 2026-10-12 14:11 UTC

Executive summary

Alaunos Therapeutics filed six 8-K forms over the past 12 months, predominantly reporting amendments to bylaws (Items 3.01) and other corporate events (Items 8.01, 9.01) with no material financing activity disclosed. The filing pattern shows routine corporate governance updates in April and October 2026, plus three consecutive filings in May–June 2026 reporting unspecified 'other events' and financial statements or exhibits. Critically, the data provided contains no quantified financial metrics, revenue figures, clinical trial progress, or disclosed shelf offerings, limiting substantive risk assessment.

Dilution risk 2/5

No ATM offerings, shelf registrations, or equity issuance details appear in the six 8-K filings analyzed. Two filings report Item 3.01 (bylaws amendments), which may relate to capitalization changes, but no concrete evidence of active dilution is present in the submission data. Routine 8.01 and 9.01 filings lack sufficient narrative detail to assess equity raise activity.

No ATM or shelf capacity disclosed across any filing
Items 3.01 (April 2026, October 2026) note bylaw amendments but lack quantified dilution detail
No sales agents or offering agreements identified

Notable filings (6)

2026-04-15 8-K	Amendment to articles of incorporation or bylaws filed (Item 3.01) · filing Routine corporate governance update, possibly affecting share structure or voting rights; specific amendment terms not detailed in submission data.
2026-05-18 8-K	Other event and financial statements or exhibits filed (Items 8.01, 9.01) · filing Disclosure of unspecified corporate event and attached exhibits; insufficient detail to assess materiality or impact.
2026-05-26 8-K	Other event and financial statements or exhibits filed (Items 8.01, 9.01) · filing Second consecutive disclosure of unspecified event and exhibit within eight days; pattern suggests multiple announcements clustered in late May 2026.
2026-06-29 8-K	Other event and financial statements or exhibits filed (Items 8.01, 9.01) · filing Third consecutive disclosure of unspecified event and exhibit; end of May–June cluster suggests potential announcement of clinical, operational, or financial milestone.
2026-09-22 8-K	Material agreement, other event, and financial statements filed (Items 1.01, 8.01, 9.01); Item 9.01 cross-references Item 1.01 · filing Company entered into or materially amended a significant agreement; filer cross-referenced material agreement in exhibit section, suggesting contract execution or substantial revision.
2026-10-09 8-K	Amendment to articles of incorporation or bylaws filed (Item 3.01) · filing Second bylaw or charter amendment in six-month period; may indicate ongoing capitalization or governance restructuring.

Financing activity

No ATM offerings, shelf registrations (S-3, 424B5), or quantified equity issuance activity disclosed in the six 8-K filings analyzed. No sales agents identified. Financing details, if any, are absent from the submission data.

Risk signals

Bylaw amendments filed in April and October 2026 without disclosed rationale; investors should review full amendment text for capitalization or voting changes via SEC Edgar.
Three consecutive Item 8.01/9.01 filings (May 18, 26, June 29, 2026) report unspecified corporate events; lack of narrative detail obscures whether announcements are routine or material.
Material agreement filed September 22, 2026 (Item 1.01) with cross-reference in exhibits; terms, counterparty, and financial impact not summarized in submission data.
No revenue, cash position, or clinical trial milestone data provided in filing abstracts; unable to assess operational or financial health from 8-K submissions alone.
Absence of shelf registration or ATM offering detail limits visibility into potential near-term financing plans or dilution trajectory.
Clustering of 8.01 and 9.01 filings in May–June 2026 may indicate compressed disclosure window; investors should review exhibit filings for context.

Bottom line

Alaunos Therapeutics' recent 8-K filings reveal routine bylaw updates and an undisclosed material agreement, but lack substantive financial, clinical, or quantified dilution metrics. Given the scarcity of narrative detail in the submission data, investors should obtain and review the complete 8-K documents and exhibits via the SEC Edgar database to assess the company's operational status, financing plans, and any material contract obligations that may affect equity value.

View this report online